PWRD yields 0.17% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 5
Combined, PWRD + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PWRD + JNJ for your $10,000?
PWRD is a concentrated stock portfolio of companies perceived to drive and benefit from the energy transition to net zero carbon emissions. Using a proprietary framework, the fund screens the broad US equity market to select companies with a strategy to reduce or enable decarbonization at scale. Selection combines a top-down analysis of the economy with a bottom-up, industry-by-industry, and company-by-company assessment. The adviser does not use sustainability ratings or rankings to exclude companies or sectors. As a result, the portfolio may focus on the most carbon-intensive industries in order for the adviser to drive change through its proxy voting guidelines. Such guidelines encourage companies to invest in their employees, communities, customers, and the environment. The adviser has discretion to target specific investment opportunities. Prior to October 13, 2023, the fund was called the Engine No. 1 Transform Climate ETF. Prior to Feb. 3, 2025, the fund had a ticker of NETZ.
Full PWRD Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.